Indivior Pays $600 Million to Settle DOJ Probe Into Suboxone

Indivior Solutions has agreed to pay $600 million to resolve criminal and civil investigations into its marketing of the opioid addiction treatment Suboxone Film (buprenorphine/naloxone).

The company pleaded guilty to making false statements about the product’s safety for children and agreed to pay $289 million. It also agreed to pay $300 million to settle charges that its marketing of Suboxone led to false claims to public healthcare programs.

Separately, Indivior will pay $10 million to settle allegations by the Federal Trade Commission that it engaged in anticompetitive activities to block generic competition for Suboxone.